Table 1.
Translational study cohort
| Patients with blocks (n = 1115) | Patients without blocks (n = 905) | ABCSG Trial 6 (n = 2020) | P value | |
|---|---|---|---|---|
| Age (years) | 0.25 | |||
| Median (Q1-Q3) | 64.8 (57.8-70.7) | 64.2 (58.1-69.9) | 64.6 (58.0-70.3) | |
| Min-Max | 40.9-80.7 | 44.2-80.5 | 40.9-80.7 | |
| Age (years), n (%) | 0.12 | |||
| ≤50 | 30 (2.7) | 21 (2.3) | 51 (2.5) | |
| 51-60 | 332 (29.8) | 270 (29.8) | 602 (29.8) | |
| 61-70 | 430 (38.6) | 389 (43.0) | 819 (40.5) | |
| ≥70 | 323 (29.0) | 225 (24.9) | 548 (27.1) | |
| Tumor size, n (%) | 0.76 | |||
| pT1 | 653 (58.6) | 517 (57.1) | 1170 (57.9) | |
| pT2 | 428 (38.4) | 354 (39.1) | 782 (38.7) | |
| pT3 | 30 (2.7) | 29 (3.2) | 59 (2.9) | |
| Missing | 4 (0.4) | 5 (0.6) | 9 (0.4) | |
| Nodal status, n (%) | 0.81 | |||
| 0 nodes | 691 (62.0) | 553 (61.1) | 1244 (61.6) | |
| 1-3 nodes | 293 (26.3) | 230 (25.4) | 523 (25.9) | |
| 4-10 nodes | 95 (8.5) | 87 (9.6) | 182 (9.0) | |
| >10 nodes | 32 (2.9) | 30 (3.3) | 62 (3.1) | |
| Missing | 4 (0.4) | 5 (0.6) | 9 (0.4) | |
| Tumor grade local, n (%) | 0.07 | |||
| G1, G2, GX | 888 (79.6) | 683 (75.5) | 1571 (77.8) | |
| G3 | 223 (20.0) | 217 (24.0) | 440 (21.8) | |
| Missing | 4 (0.4) | 5 (0.6) | 9 (0.4) | |
| Estrogen receptor local, n (%) | <0.0001 | |||
| Negative | 17 (1.5) | 37 (4.1) | 54 (2.7) | |
| Positive | 1081 (97.0) | 814 (89.9) | 1895 (93.8) | |
| Missing | 17 (1.5) | 54 (6.0) | 71 (3.5) | |
| Progesterone receptor local, n (%) | <0.0001 | |||
| Negative | 239 (21.4) | 161 (17.8) | 400 (19.8) | |
| Positive | 855 (76.7) | 690 (76.2) | 1545 (76.5) | |
| Missing | 21 (1.9) | 54 (6.0) | 75 (3.7) | |
| Type of surgery, n (%) | 0.50 | |||
| Breast conserving | 617 (55.3) | 479 (52.9) | 1096 (54.3) | |
| Mastectomy | 494 (44.3) | 421 (46.5) | 915 (45.3) | |
| Missing | 4 (0.4) | 5 (0.6) | 9 (0.4) | |
| Treatment arm, n (%) | 0.003 | |||
| Tamoxifen | 590 (52.9) | 418 (46.2) | 1008 (49.9) | |
| Tamoxifen + aminoglutethimide | 525 (47.1) | 487 (53.8) | 1012 (50.1) |
ABCSG, Austrian Breast and Colorectal Cancer Study Group.